Sign up
Pharma Capital

PureTech Health affiliate resTORbio raises another US$40mln as age-related trial progresses

The funding brings equity investment in resTORbio so far this year to US$65mln
picture of elderly
TORC1 is a key pathway involved in aging

PureTech Health PLC (LON:PRTC) affiliate resTORbio has raised US$40mln through an oversubscribed funding run led by OrbiMed.

Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio took part and the funding brings equity investment in resTORbio so far this year to US$65mln.

 Daphne Zohar, chief executive, said she was extremely pleased with the progress made by resTORbio, which has a programme for aging-related diseases and conditions that selectively targets TORC1, a key pathway involved in aging.

A Phase 2b clinical study is underway and designed to assess its safety, tolerability and efficacy reducing respiratory tract infections (RTIs) in the elderly.

Top-line results are expected in the second half of 2018.  


Register here to be notified of future PRTC Company articles
View full PRTC profile

PureTech Health Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.